They join the company's founders Bob Mulroy and Debasish Roychowdhury as directors.
Hukkelhoven is a senior analyst at healthcare investment firm Perceptive Advisors; she also serves on the board of MeiraGTx. She received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. Hukkelhoven graduated magna cum laude from Princeton University with degrees in Molecular Biology and Finance.
Gould is a partner and head of venture growth equity investments with Adams Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. He also sits on the board of directors of Aptinyx, Atox Bio, Corvus Pharmaceuticals, Fusion Pharmaceuticals, LifeBond, Orbus Therapeutics and Outpost Medicine.
PTx is an integrated commercial stage biotech company focused on the development and commercialisation of therapeutics that improve health and economic outcomes in the treatment of cancer.
Its development focus spans the entire range of cancer therapy from primary treatments to supportive care.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer